WilmerHale Reps Eleven Biotherapeutics in License Agreement with Roche for Antagonist Antibody Technology

WilmerHale Reps Eleven Biotherapeutics in License Agreement with Roche for Antagonist Antibody Technology

News

WilmerHale represented Eleven Biotherapeutics, a biopharmaceutical company researching and developing protein therapeutics to treat diseases of the eye, in the negotiation of a license agreement with Roche for Eleven's IL-6 antagonist monoclonal antibody program, including its preclinical ophthalmic drug EBI-031.

The agreement was signed in June; its effectiveness is subject to approval by Eleven's stockholders. Assuming such approval is obtained, Eleven would be entitled to a $7.5 million upfront, and up to $262.5 million in future milestone, plus royalties.

The WilmerHale team consisted of Partner Belinda Juran and Associates Alex Civetta and Ritu Gupta on the license agreement, and Partners Brian Johnson and Hal Leibowitz and Counsel Chris Barnstable-Brown leading the corporate matters.

Read Eleven Biotherapeutics' press release for more information.